Megan Briskman is an associate in Weil’s Technology & IP Transactions practice and is based in New York. Ms. Briskman participates in the representation of Firm clients in a variety of matters relating to the licensing, acquisition, development, sale, use and commercial exploitation of intellectual property and technology. Ms. Briskman was previously a member of the Firm’s Mergers & Acquisitions practice where she participated in advising public and private companies in mergers, acquisitions and divestitures.
Ms. Briskman has been part of the teams advising:
- Aterian Investment Partners in its acquisition of Stewart Tubular Products, Inc.
- Brookfield Asset Management Inc. and Brookfield Property Partners L.P. (BPY) in BPY's $14.4 billion acquisition of the approximately 66% of common stock that it did not already own of GGP Inc. (f/k/a General Growth Properties Inc.)
- First Data Corporation in its $750 million acquisition via cash tender offer of CardConnect Corp.
- IMS Health Holdings, Inc. in its $17.6 billion all-stock merger of equals with Quintiles Transnational Holdings Inc.
- L’Oréal USA (a subsidiary of L’Oréal S.A.) in its $1.3 billion acquisition of the CeraVe, AcneFree and AMBI skincare product brands from Valeant Pharmaceuticals International, Inc. (n/k/a Bausch Health Companies)
- MGM Resorts International in its $1.175 billion sale of the real property of the Borgata Hotel Casino & Spa in Atlantic City, New Jersey to MGM Growth Properties LLC
- OMERS Private Equity in, together with Harvest Partners, the approximately $1 billion take-private acquisition of Epiq Systems, Inc.
- Signet Jewelers Limited in its $328 million acquisition of R2Net, Inc.
Ms. Briskman received her J.D. from New York University School of Law and her B.A., summa cum laude, from Wake Forest University.